Condition: Soft Tissue Sarcoma · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Objective to evaluate the efficacy and safety of candonilimab combined with anlotinib in the treatment of progressive or metastatic soft tissue sarcoma that failed previous first-line standard therapy.
This description comes directly from the study's public registry record.
Ying Dong · 13666669105 · dongying74@zju.edu.cn
Rui Bai · 15858224043 · whiterui411@zju.edu.cn
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05926700